Menu
Recruiting NCT06537037

Exploring the Association of Imaging and Tumor Microenvironment in Urologic Cancer Using Radiogenomic Approach(Radiogenomics-Urinary)

Observational Urologic Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Urologic Cancer. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This is the prospective, observational cohort study (Radiogenomics-Urinary), which aims to explore the relationship between the imaging information of urologic cancer patients, tumor microenvironment and the prognosis of urologic cancer patients.

Primary outcome measures

  • Correlation analysis of sequencing results and body composition [Time frame: 0.5 year]
  • Correlation analysis of sequencing results and tumor radiomic features [Time frame: 0.5 year]
Secondary outcome measures (2)
  • Constructing tumor microenvironment prediction model [Time frame: 2 years]
  • Constructing a multi-dimensional prognostic prediction model [Time frame: 3 years]

Eligibility criteria

Inclusion criteria

  • Patients treated for urologic cancer in Wuhan Union Hospital from August 2024 to August 2027;
  • Aged > 18 years old;
  • At least one CT scan or MRI scan before treatment;
  • Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.

Exclusion criteria:

  • Poor image quality;
  • Incomplete clinical data or loss of follow-up;
  • Presence of another primary malignancy other than urologic cancer;
  • Unclear pathological diagnosis。

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Union Hospital,Tongji Medical College,Huazhong University of Science and Technology — Wuhan

Identifiers

NCT: NCT06537037 · S187

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗